Medical Disclaimer
Dose GLP-1 is a consumer information website, not a medical practice. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations.
GLP-1 medications are prescription drugs that require a licensed prescriber. Dosing, safety, and appropriateness depend on your individual medical history, which only your healthcare provider can evaluate. Always consult your doctor, pharmacist, or other qualified clinician before starting, stopping, or adjusting any medication.
If you are experiencing a medical emergency, call 911 or your local emergency number immediately.
Our Mission
More than 12% of American adults have been prescribed a GLP-1 medication — yet most of the information available online is either clinical (written for prescribers) or commercially driven (written to sell something). The middle ground — plain-language, source-cited consumer information — is largely missing.
Dose GLP-1 exists to fill that gap. We write about side effects, affordability, what happens when you stop, how insurance coverage works, and how the drugs compare to each other. We don't sell anything and we don't earn commissions. Every factual claim is cited.
Methodology & Sources
Every page on this site is written against a defined source hierarchy:
- FDA-approved prescribing information (package inserts) — the primary source for dosing, approved indications, and labeled side effects
- NIH National Library of Medicine publications and MedlinePlus drug information
- Peer-reviewed Phase 3 clinical trial data (SUSTAIN, STEP, SURMOUNT, and SURPASS trial families)
- FDA drug approval announcements and safety communications
- CDC and CMS data for coverage and prevalence statistics
We do not cite press releases, manufacturer marketing materials, patient forums, or news articles as primary sources. When secondary sources are referenced, the underlying primary source is traced.
Pages are reviewed and updated on a quarterly schedule, or sooner when the FDA issues a new safety communication or label change.
Editorial Independence
Dose GLP-1 has no commercial relationships that influence editorial content. We do not accept sponsored posts, paid placements, or manufacturer-sponsored content of any kind. There are no affiliate links.
In a future phase, we may add telehealth affiliate links (referral relationships with prescribing services). If and when that happens, all such relationships will be disclosed clearly on every relevant page. Editorial content will remain separated from any commercial content, and drug information pages will not carry affiliate links.
What We Cover
We focus on the questions that people on GLP-1 medications — or considering them — actually ask:
- Side effects — what to expect, how long they last, what to do about them
- Affordability — manufacturer savings programs, pharmacy pricing, insurance coverage, and compounding
- Stopping — what happens when you discontinue, how to taper, and the evidence on weight regain
- Drug comparisons — how Ozempic, Wegovy, Mounjaro, and Zepbound differ on efficacy, cost, and dosing
- Research updates — new trial data, label changes, and coverage policy shifts
We do not cover: prescribing decisions, individual treatment suitability, off-label uses, or compounded medications in clinical detail. For those questions, talk to your prescriber.
Contact
Dose GLP-1 is an independent publication. For editorial feedback, factual corrections, or source questions, reach us at:
Email: [email protected]
We welcome corrections. If you find a factual error or an out-of-date source citation, please let us know and we will review and update promptly.
We do not provide individual medical advice by email or any other channel.
Stay Updated
We publish a free weekly digest every Monday covering FDA decisions, coverage changes, and new clinical trial data. No spam — just the week's relevant GLP-1 developments in plain language.